3,470
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Alantolactone alleviates collagen-induced arthritis and inhibits Th17 cell differentiation through modulation of STAT3 signalling

, , , &
Pages 132-143 | Received 06 Oct 2020, Accepted 09 Jan 2021, Published online: 08 Feb 2021
 

Abstract

Context

Alantolactone, the bioactive component in Inula helenium L. (Asteraceae), exhibits multiple biological effects.

Objective

We aimed to determine the anti-inflammatory effect of alantolactone in a collagen-induced arthritis (CIA) mouse model and its immunomodulatory effects on Th17 differentiation.

Materials and methods

A CIA mouse model was established with DBA/1 mice randomly divided into four groups (n = 6): healthy, vehicle and two alantolactone-treated groups (25 or 50 mg/kg), followed by oral administration of alantolactone to mice for 21 consecutive days after arthritis onset. The severity of CIA was evaluated by an arthritic scoring system and histopathological examination. Levels of cytokines and anti-CII antibodies as well as percentages of splenic Th17 and Th17 differentiation with or without alantolactone treatments (0.62, 1.2 or 2.5 μM) were detected with ELISA and flow cytometry, respectively. Western blot analysis was used to evaluate intracellular signalling in alantolactone-treated spleen cells.

Results

In CIA mice, alantolactone at 50 mg/kg attenuated RA symptoms, including high arthritis scores, infiltrating inflammatory cells, synovial hyperplasia, bone erosion and levels of the proinflammatory cytokines TNF-α, IL-6 and IL-17A, but not IL-10 in paw tissues. Alantolactone also reduced the number of splenic Th17 cells and the capability of naïve CD4+ T cells to differentiate into the Th17 subset by downregulating STAT3/RORγt signalling by as early as 24 h of treatment.

Discussion and conclusions

Alantolactone possesses an anti-inflammatory effect that suppresses murine CIA by inhibiting Th17 cell differentiation, suggesting alantolactone is an adjunctive therapeutic candidate to treat rheumatoid arthritis.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from either of the corresponding authors, Chi Chien Lin or Kuo Tung Tan, upon reasonable request.

Additional information

Funding

The present study was supported by grants from Taichung Veterans General Hospital [Grant No. TCVGH-1097309C and TCVGH-1107307C] and the Animal Biotechnology Center from the Feature Areas Research Center Program of the Taiwan Ministry of Education [Grant No. MOE-107-S-0023-E].